RZLT

In a report released yesterday, Edward Nash from Canaccord Genuity initiated coverage with a Buy rating on Rezolute (RZLT – Research Report) and a price target of $17.00. The company's shares closed last Tuesday at $3.15, close to its 52-week low of $2.26. According to TipRanks.com, Nash is a 1-star analyst with an average return of -2.2% and a 35.2% success rate. Nash covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Galmed Pharmaceuticals, and Corcept Therapeutics. Currently, the analyst consensus on Rezolute is a Strong Buy with an average price target of $13.75.
https://www.tipranks.com/news/blurbs/rezolute-rzlt-initiated-with-a-buy-at-canaccord-genuity?utm_source=advfn.com&utm_medium=referral